Stay updated with breaking news from Expanded Access Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Q2 2023 Earnings Call Transcript August 15, 2023 TFF Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.14 EPS, expectations were $0.2. Operator: Good morning, ladies and gentlemen, and welcome to the TFF Pharmaceuticals Second Quarter 2023 Corporate Update and Earnings Conference Call. As a reminder, this conference is being […]
RHB-107 included in the U.S. Department of Defense-supported ACESO PROTECT multinational platform trial for early COVID-19 outpatient treatment; The...
Delcath Systems, Inc. announced that the US Food and Drug Administration approved HEPZATO KIT as a liver-directed treatment for adult patients with metastatic uveal melanoma with unresectable... -Yesterday at 09:10 pm- MarketScreener
A deconstructed view on Delcath Systems' (NASDAQ: DCTH) latest FDA approval and key points that are important for investors to understand.
Melphalan/hepatic delivery system (Hepzato Kit; Delcath Systems Inc) is currently the only liver-directed therapy approved by the FDA for the treatment of netastatic uveal melanoma and percutaneous hepatic perfusion.